soft.report

IOP from an implantable sensor tracked visual field progression in glaucoma

In a 9-eye study published in the BJO, mean IOP recorded by a sulcus-implanted sensor was associated with visual field progression in primary open-angle glaucoma, whereas single in-office Goldmann readings were not.

Published Source date: November 15, 2026 soft.report Team

Intraocular pressure (IOP) varies throughout the day, yet in clinic it is usually measured only a few times a year. A study published in November 2026 in the British Journal of Ophthalmology (BJO) examined whether continual self-monitoring with an implantable sensor explains glaucoma progression better than Goldmann applanation tonometry (GAT).

What was done

This prospective, multicenter study included eyes with primary open-angle glaucoma that had received the EYEMATE-IO system, an IOP sensor implanted in the ciliary sulcus. Participants were enrolled in the 3-year ARGOS-03 follow-up study (registration NCT03651336) and were asked to measure their IOP with the system at least four times a day at different times.

For each interval between two visual field tests, the investigators calculated mean IOP, peak IOP, and IOP fluctuation from both the sensor and GAT, and analyzed their association with the rate of visual field progression using mixed-effects models.

What they found

  • Nine eyes of 9 patients were included, with a mean follow-up of 2.9 ± 0.2 years.
  • Between two visual field tests there were on average 4,082.8 IOP readings per patient with the sensor (range 1,652 to 7,152), versus 2.1 with GAT.
  • Mean IOP recorded by the sensor was significantly associated with visual field progression (coefficient −0.21; 95% CI −0.34 to −0.07; p = 0.003).
  • Mean in-office IOP measured by GAT showed no significant association with progression (p = 0.450).
  • Results were similar when sensor readings taken during office hours and outside office hours were analyzed separately.

Limitations

  • The sample is very small (9 eyes), which limits the precision of the estimates and their generalizability.
  • All participants had the implanted sensor, a selected group that does not represent most patients with glaucoma.
  • The design is observational: it shows an association and does not prove that sensor-guided IOP management changes the course of the disease.
  • The comparison relied on very few GAT readings per interval, which by design favors the method with thousands of measurements.

Why it matters in practice

The study underlines a known weakness of single-point IOP measurements: they may miss the true pressure exposure that drives progression. Home or continual monitoring may eventually help explain why some patients progress despite IOP that looks controlled in the office. For now, the data are preliminary and need confirmation in larger studies, ideally with treatment outcomes.

Read the original paper in the British Journal of Ophthalmology.

Sources

  1. IOP monitoring with an implantable sensor predicts visual field progression in the EYEMATE-IO trial — British Journal of Ophthalmology, November 15, 2026

Informational content, written with AI assistance from the cited sources. It does not replace reading the original study or a medical evaluation.

Ophthalmology reports in your own template

The AI reads the exam, drafts the report in your template, and you review and sign. 15-day free trial, no card.

Discover soft.report

Read also